Triterpene Derivatives for HIV Activity Across Gag Polymorphisms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a strong need for new drugs with novel structures and mechanisms of action to effectively treat HIV-mediated diseases, as existing treatments like bevirimat do not provide robust viral load reduction in all patients due to genetic polymorphisms.
Innovation Solution
Development of novel triterpene derivatives, including compounds of formula (I) and their pharmaceutically acceptable salts, which are designed to inhibit HIV maturation and replication, offering a new therapeutic approach.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bevirimat is used to treat HIV, then viral load reduction is achieved in some patients, but treatment response is inconsistent due to Gag polymorphisms
Solution Approach 1:
The patent modifies the chemical structure of betulinic acid by changing parameters at specific positions (C-3 hydroxyl group substitutions, C-17 carboxyl group modifications) to create derivatives with improved activity against HIV strains with Gag polymorphisms, thereby achieving more consistent treatment response across different viral variants
2Reliability
If novel triterpene derivatives are developed, then potential anti-HIV activity is achieved, but extensive chemical synthesis and screening are required
Solution Approach 1:
The patent systematically modifies specific segments of the betulinic acid molecule (C-3 position substituents, C-17 position carboxyl group derivatives) independently, allowing for modular synthesis and screening of multiple derivatives with relatively simplified approaches compared to de novo synthesis of completely new structures
Solution Approach 2:
The patent employs structure-activity relationship analysis based on known betulinic acid activity to guide the design of derivatives, performing preliminary computational or in silico screening to identify promising candidates before extensive synthetic work, thereby reducing the overall complexity of the development process
Data Source
AI summary
The present invention relates to novel triterpene derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and ringare as defined herein. The invention also relates to novel triterpene derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.